Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01746095
Recruitment Status : Completed
First Posted : December 10, 2012
Last Update Posted : December 9, 2014
Sponsor:
Collaborators:
Synteract, Inc.
Cystic Fibrosis Foundation
Information provided by (Responsible Party):
Savara Inc.

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 June 1, 2019
(Canceled on June 20, 2019)
June 24, 2019
July 19, 2019
2 September 19, 2019
October 7, 2019